meticrane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1777 1084-65-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • meticrane
  • meticran
  • arresten
  • Molecular weight: 275.34
  • Formula: C10H13NO4S2
  • CLOGP: 0.48
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 94.30
  • ALOGS: -2.61
  • ROTB: 1

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.112 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 8.072 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.959 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.218 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 66.870 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 82.720 % High 1
herg hERG pIC50 4.121 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.191 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.027 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 74.820 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,STK33,TEK 32
kinase-selectivity-class AXL,GRK2,MAP2K6,PDK1,TEK,ZAP70 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.321 High 1
mh-clint Mouse hepatocyte intrinsic clearance 3.192 High 1
mppb Mouse plasma protein binding (% unbound) 73.540 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.631 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 84.330 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.426 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 93.960 % High 1
rppb Rat plasma protein binding (% unbound) 65.480 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 781.628 uM High 1

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C03BA09 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, EXCL. THIAZIDES
Sulfonamides, plain
CHEBI has role CHEBI:35554 cardiovascular drug

Related Drugs by ATC class:

C03BA Sulfonamides, plain 10 drugs
chlortalidoneclofenamideclopamideclorexolonefenquizoneindapamidemefrusidemetolazonequinethazonexipamide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.05 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01605 KEGG_DRUG
C0873165 UMLSCUI
CHEBI:31839 CHEBI
CHEMBL1318341 ChEMBL_ID
DB13284 DRUGBANK_ID
4165 PUBCHEM_CID
2133 INN_ID
I7EKN1924Q UNII
008193 NDDF
I7EKN1924Q INXIGHT DRUGS

Pharmaceutical products:

None